Search results for

Convicted cybersquatters in the Philippines could be sent to jail for up to 12 years if the country’s House of Representatives approves a bill that the Senate passed yesterday

TMview, which enables users to search trade marks across offices in Europe, was relaunched yesterday.

As more blockbuster drugs tumble off the patent cliff this year, the generic industry is set to become more profitable than ever - but the spike in competition means generics may also have to become more brand-savvy

Heads of government at today’s EU Council meeting will be discussing the euro, youth unemployment and boosting enterprise - but they may also find time to break the deadlock on the planned unitary patent

ARI Registry Services signed 21 gTLD clients within one week of the application period opening on January 12, chief executive Adrian Kinderis said today.

The industry networker I use social media both personally and professionally. I'm also the company's social media attorney, so I'm involved with marketing and human resources as to how we and our employees use various social media platforms. Having said that, while I'm therefore more familiar with social media I wouldn't say I'm an expert. Anyone can make good use of the various platforms without much training or awareness in advance – it's simply a case of getting used to how each one functions and the internal customs and practices.

Jeremy Cubert and Eric Silverman introduce readers to Pharmville, USA, a futuristic community of inventors operating after full implementation of the America Invents Act

Benjamin Bai explains why a US decision that expands the jurisdiction of the ITC in trade secrets cases may be flawed, and contrasts it with the limited approach of the Supreme People’s Court in China

The in-house IP lawyer is often given responsibility for social media policy, even though many of the issues are nothing to do with IP infringement. Carmen Glatt and Kim Scallan give some advice on coping with the role

This year $50 billion worth of drugs come off patent. The pharma industry’s response will be to focus on personalised medicine and biologics. Eileen McDermott explains how this will shift IP strategy towards trade secrets, data and patenting processes